NEW YORK, NY / ACCESSWIRE / February 11, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
OSH Shareholders Click Here: https://www.zlk.com/pslra-1/oak-street-health-inc-loss-submission-form?prid=23629&wire=1
BMBL Shareholders Click Here: https://www.zlk.com/pslra-1/bumble-inc-loss-submission-form?prid=23629&wire=1
BIIB Shareholders Click Here: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form-2?prid=23629&wire=1
* ADDITIONAL INFORMATION BELOW *
Oak Street Health, Inc. (NYSE:OSH)
OSH Lawsuit on behalf of: investors who purchased August 6, 2020 - November 8, 2021
Lead Plaintiff Deadline: March 14, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/oak-street-health-inc-loss-submission-form?prid=23629&wire=1
According to the filed complaint, during the class period, Oak Street Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Oak Street maintained relationships with third-party marketing agents likely to provoke law enforcement scrutiny; (2) Oak Street was providing free transportation to federal health care beneficiaries in a manner that would provoke law enforcement scrutiny; (3) these activities may be violations of the False Claims Act; (4) as such, Oak Street was at heightened risk of investigation by the U.S. Department of Justice and/or other federal law enforcement agencies; (5) as a result, Oak Street was subject to adverse impacts related to defense and settlement costs and diversion of management resources; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Bumble Inc. (NASDAQ:BMBL)
This lawsuit is on behalf of all purchasers of the Class A common stock of Bumble directly in Bumble's secondary public stock offering which took place on or about September 10, 2021.
Lead Plaintiff Deadline: March 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/bumble-inc-loss-submission-form?prid=23629&wire=1
According to the filed complaint, (a) Bumble's paying user growth trends had abruptly reversed in 3Q21 and the Company had actually lost tens of thousands of paying users during the quarter; (b) paying users had been more reluctant to sign up for the Bumble app during 3Q21 because of the recent price hike for paid services on the app; (c) a material number of paying users were leaving the Badoo app, a dating-focused social network, and/or could not make payments through the Badoo app due, in substantial part, to problems arising from the Company's transition of its payment platform; and (d) as a result of the foregoing, Bumble's business metrics and financial prospects were not as strong as the Registration Statement had represented.
Biogen Inc. (NASDAQ: BIIB)
BIIB Lawsuit on behalf of: investors who purchased June 7, 2021 - January 11, 2022
Lead Plaintiff Deadline: April 8, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biogen-inc-loss-submission-form-2?prid=23629&wire=1
According to the filed complaint, during the class period, Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) there was a significant, undisclosed lobbying campaign between Biogen and the Food and Drug Administration ("FDA") that was instrumental in the decision to file and approve Aduhelm, a drug being developed to treat Alzheimer's disease; 2) the Phase III ENGAGE study demonstrated that Aduhelm failed to achieve a clinical benefit to Alzheimer's patients; 3) ENGAGE was a failed study from which Biogen concluded not to seek FDA approval for Aduhelm in 2019; and 4) defendants misled investors as to the way in which approval was achieved, that the clinical data did not support a clinical benefit by taking Aduhelm and that side-effects were dangerous and serious
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP